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ABSTRACT
Tuberous sclerosis (TSC) is an inherited tumour syndrome caused by mutations 
in TSC1 or TSC2 that lead to aberrant activation of mTOR. Tumour responses in TSC 
patients to rapamycin, an allosteric inhibitor of mTOR, or its analogs are partial and 
reversible probably due to feedback activation of Akt. In this study, we examined 
the efficacy of GSK2126458, an ATP-competitive dual inhibitor of PI3K/mTOR, in 
comparison to rapamycin for treatment of renal tumours in genetically engineered 
Tsc2+/- mice. We found that both GSK2126458 and rapamycin caused significant 
reduction in number and size of solid renal tumours. GSK2126458 also significantly 
reduced the number and size of all lesions (cystic, papillary and solid) although to a 
lesser extent compared to rapamycin. GSK2126458 inhibited both PI3K and mTOR 
while rapamycin exerted stronger inhibitory effect on mTORC1 in renal tumours. 
Furthermore, GSK2126458 and rapamycin suppressed proliferation of tumour cells. 
Importantly, GSK2126458 increased apoptosis of solid tumours but rapamycin 
did not. Further investigations are therefore needed to test whether rapamycin in 
combination with GSK2126458 could promote apoptosis and thus improve therapy 
of TSC-associated renal tumours.
INTRODUCTION
Tuberous sclerosis (TSC) is an inherited disease 
caused by mutations in TSC1 or TSC2 that lead to 
aberrant activation of mTOR and development of 
tumours in multiple organs. TSC patients frequently 
develop renal manifestations, usually multiple and 
bilateral angiomyolipomas (AML) that are the leading 
cause of adult deaths from the disease. Renal cysts are 
also commonly observed and renal cell carcinoma (RCC) 
develops in around 2% of TSC patients [1]. Treatment 
with the mTOR inhibitor rapamycin (sirolimus) or its 
derivative everolimus significantly reduces the size of 
renal AML in TSC patients [2–4]. Everolimus has also 
demonstrated clinical efficacy in TSC-associated renal 
carcinoma [5]. However, responses of AML and other 
TSC-associated tumours to these mTOR inhibitors are 
partial and tumours that initially respond to treatment 
usually regrow after drug withdrawal. Partial resistance to 
rapamycin or its derivatives is suggested to be associated 
with loss of negative feedback regulation that leads to 
increased phosphorylation and activation of AKT [6].
To prevent feedback activation of Akt, ATP-
competitive dual inhibitors of PI3K/mTOR have been 
developed and used in clinical trials for cancer therapy [7]. 
GSK2126458 is a highly potent and orally bioavailable 
dual ATP-competitive inhibitor of PI3K and mTOR [8]. 
Preclinical studies suggest that GSK2126458 inhibits 
proliferation of a variety of cancer cell lines and tumours 
in xenograft mouse models with induction of apoptosis 
and attenuation of the PI3K/Akt/mTOR activity [8, 9]. A 
recent phase I clinical trial indicates that GSK2126458 
is well tolerated in patients across multiple solid 
malignancies. Tumour responses and disease stabilization 
were documented in patients with several tumour types 
including bladder and renal cell carcinoma [10].
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Tsc2+/- mice spontaneously develop various lesions 
in the kidneys including cysts, papillary adenomas, 
solid adenomas and carcinomas [11]. These lesions are 
associated with aberrant activation of the PI3K/Akt/
mTOR signalling pathway [12]. In this study, we tested 
the efficacy of GSK2126458 compared to rapamycin for 
treatment of renal lesions in Tsc2+/- mice.
RESULTS
Activation of oncogenic pathways in renal 
tumours of Tsc2+/- mice
The kidneys of adult Tsc2+/- mice developed lesions 
including cysts, papillary adenoma, solid adenoma 
and carcinoma (Figure 1). Lesions varied in size from 
microscopic intraepithelial neoplasias to macroscopic 
carcinomas. Tumour cells were larger than adjacent 
normal cells and had hyper-chromatic enlarged nuclei. 
Lesions had aberrant activation of the mTOR complex 
1 (mTORC1) and mTORC2 as evidenced by the 
increased phosphorylation of mTOR, Akt, PKCα, S6 
and 4E-BP1 compared to the adjacent normal tissues 
(Figure 2). In addition to mTOR, Akt has many other 
substrates [13]. Akt substrates (RXXS*/T*) and Akt 
substrates (RXRXXS*/T*) were highly phosphorylated 
in renal lesions (Supplementary Figure 1). The MAPK 
pathway was also activated in these lesions as indicated 
by increased phosphorylation of RAF1 and Erk1/2 
(Supplementary Figure 2).
Efficacy of GSK2126458 and rapamycin on renal 
tumours of Tsc2+/- mice
To test the anti-tumour efficacy of GSK2126458, 
we first determined the maximum tolerated dose (MTD) 
of GSK2126458 in Tsc2+/- mice in a two weeks’ pilot 
study. Daily doses greater than 2 mg/kg of GSK2126458 
via intraperitoneal injection caused significant loss of 
body weight or diarrhoea or both, with symptoms in 
female Tsc2+/- mice more severe than in males. This 
maximum tolerated dose was therefore used in this 
study. For comparison, 3 groups of 10 mice each were 
treated for two months from the age of 12 months with 
Figure 1: Renal tumours in Tsc2+/- mice. Kidney sections were prepared from 14 months old Tsc2+/- mice and HE-stained. 
Representative renal lesions including micro-lesions (micro-cystic, MC; micro-papillary, MP; micro-solid, MS also referred to as 
microscopic intraepithelial neoplasia), cysts (C), papillary adenomas (P), and solid tumours (S). Black lines are scale bars.
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vehicle, GSK2126458 (2 mg/kg) or rapamycin (4 mg/kg). 
Tumour burden was compared by analysing both solid 
renal tumours only and renal lesions of all types. Both 
GSK2126458 and rapamycin significantly reduced total 
number (P=0.0404; P=0.0003), size (P=0.0281; P<0.0001) 
and cellular area (P=0.0345; P<0.0001) of solid renal 
tumours (Figure 3, Supplementary Table 1). Similarly, 
both GSK2126458 and rapamycin significantly reduced 
total number (P=0.0448; P<0.0001), size (P=0.0185; 
P<0.0001) and cellular area (P=0.0433; P<0.0001) of 
all lesion types (Figure 3, Supplementary Table 2). 
Rapamycin caused greater reduction than GSK2126458 
in number (P=0.0002), size (P=0.0039) and cellular 
area (P=0.0015) of all types of lesions but the difference 
in reduction of solid tumour burden was not significant 
between GSK2126458 and rapamycin treated mice (Figure 
3, supplementary Tables 1 and 2).
Effect of GSK2126458 and rapamycin on PI3K/
Akt/mTOR and Erk1/2 signalling in renal 
tumours of Tsc2+/- mice
Kidney sections from the mice of different treatment 
groups were used to investigate PI3K/Akt/mTOR 
signalling with IHC. Phosphorylation of S6 at S235/236 
is one of the key indicators for mTORC1-dependent 
signalling and phosphorylation of mTOR at S2481 and of 
Akt at S473 are two important indicators of mTORC2-
dependent signalling. As shown in Figure 4, decreased 
phosphorylation of mTOR at S2481, Akt at S473 and S6 
at S235/236 was observed in renal lesions of GSK2126458 
treated mice. Phosphorylation of these proteins was 
also reduced in renal lesions of rapamycin treated mice 
(Figure 4). Rapamycin exhibited a greater inhibitory 
effect on S6 phosphorylation than GSK2126458. Further 
examination of additional IHC stained kidney sections 
revealed remarkable variations in Akt phosphorylation at 
S473 in rapamycin treated renal lesions, and 57% (20/35) 
of cysts treated by rapamycin had highly phosphorylated 
Akt at S473 while GSK2126458 consistently decreased 
Akt phosphorylation in all lesions (Supplementary Figure 
3). However, no increased phosphorylation of Akt at S473 
was observed in solid tumours of rapamycin treated mice 
compared to vehicle. Consistent with these observations, 
Western analysis demonstrated that after treatment 
with GSK2126458 solid renal tumours had decreased 
phosphorylation of these proteins at the specified serine 
sites, although GSK2126458 had greater inhibitory effect 
Figure 2: PI3K/Akt/mTOR signalling in renal tumours of Tsc2+/- mice. Kidney sections prepared from 14 months old Tsc2+/- 
mice were used for IHC analysis. Representative IHC-stained sections were presented to show phosphorylation of mTOR at S2448 and 
S2481, S6 at S235/236, 4E-BP1 at T37/46 and S65, and Akt at T308 and S473 in renal tumours. Twenty cystic and 20 solid renal lesions 
from 10 Tsc2+/- mice were analysed consistently showing similar protein phosphorylation levels. Black lines are scale bars.
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Figure 3: Efficacy of GSK2126458 and rapamycin on renal tumours in Tsc2+/- mice. Tsc2+/- mice were treated from 12 months 
old for 2 months (n=10 each group). Mice were sacrificed for tumour burden assessment at the age of 14 months. Dosages are described 
in methods. Kidney sections were prepared for histological assessment of treatment efficacy. Left panel: comparison of total number and 
size (area) as well as cellular area of all lesions (cystic, papillary and solid). Right panel: comparison of total number and size (area) as 
well as cellular area of solid tumours. Horizontal bars indicate a median. For detailed statistical analysis see Supplementary Tables 1 and 2.
Figure 4: Effect of GSK2126458 and rapamycin on mTOR signalling of renal tumours in Tsc2+/- mice. Kidney sections 
prepared from 14 months old Tsc2+/- mice treated with vehicle, GSK2126458 or rapamycin were used for IHC analysis. Representative 
IHC-stained sections were presented to show phosphorylation of mTOR at S2481, S6 at S235/236 and Akt at S473 in renal tumours. Black 
lines are scale bars.
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on Akt S473 and rapamycin on S6 S235/236 (Figure 5). 
GSK2126458 reduced expression of 4E-BP1 while both 
GSK2126458 and rapamycin attenuated phosphorylation 
of 4E-BP1 at T37/46 (mTORC1 indicator) in solid 
tumours (Figure 5). In addition, GSK2126458 reduced 
phosphorylation of Akt at T308 but rapamycin did not 
in solid tumours (Figure 5). These results suggest that 
GSK2126458 inhibited both PI3K and mTOR in all 
types of renal lesions and that its effects were greater on 
mTORC2 but less on mTORC1 than rapamycin in solid 
tumours. Furthermore, GSK2126458 appeared to reduce 
phosphorylation of RAF1 at S259 but not Erk1/2 at T202/
Y204 whereas rapamycin decreased phosphorylation of 
both proteins in solid tumours suggesting that rapamycin 
suppresses MAPK signalling via multiple mechanisms.
Western blot was also used to investigate the effect 
of treatment on cellular signalling in normal tissues. Both 
GSK2126458 and rapamycin inhibited phosphorylation of 
S6 at S235/236 but did not inhibit phosphorylation of other 
proteins examined in the liver (Supplementary Figure 4). 
In the kidneys, GSK2126458 reduced phosphorylation of 
mTOR at S2481, Akt at S473, S6 at S235/236 and RAF1 
at S259. Rapamycin also reduced phosphorylation of 
these proteins although to a lesser extent, except for S6 at 
S235/236 in the kidneys (Supplementary Figure 4).
Effect of GSK2126458 and rapamycin on 
proliferation and apoptosis in renal tumours of 
Tsc2+/- mice
IHC-stained Ki67 was used to evaluate the effect 
of treatment on proliferation of renal tumour cells 
(Supplementary Figure 5). Ten fields (20x) from 10 solid 
tumours were selected randomly from each group and 
examined for quantification of Ki67-positive tumour cells 
using ImageJ. GSK2126458 and rapamycin reduced the 
median percentage of Ki67-positive cells from 18.13% to 
5.82% and 2.07% respectively (Figure 6; Supplementary 
Table 3). Rapamycin inhibited proliferation of tumour 
cells to a greater extent than GSK2126458 (P<0.0001).
Figure 5: Effect of GSK2126458 and rapamycin on mTOR/MAPK/apoptotic signalling of renal tumours in Tsc2+/- 
mice. Western blot was used to analyse mTOR/MAKP/apoptotic signalling. Proteins were prepared from solid renal tumours dissected 
from Tsc2+/- mice treated for one month with vehicle, GSK2126458 or rapamycin. Beta-actin was used as a loading control. Representative 
Western blots were presented to show phosphorylation of mTOR at S2481, Akt at T308 and S473, S6 at S235/236, 4E-BP1 at T37/46, 
RAF1 at S256, Erk1/2 at T202/Y204 and MDM2 at S166 as well as expression of 4E-BP1 and p53.
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IHC-stained active caspase 3 was used to test 
whether treatment induced apoptosis in tumours 
(Supplementary Figure 6). Ten fields (20x) from 10 
solid tumours were selected randomly from each group 
and examined for quantification of the area of active 
caspase 3-positive tumour cells using ImageJ. The total 
area of active caspase 3-positive tumour cells in each 
field is presented in Figure 6 and Supplementary Table 
3. GSK2126458 significantly increased the median total 
area of active caspase 3-positive tumour cells (P=0.0288) 
but rapamycin did not. Similar results were observed 
when cleaved PARP (another apoptosis marker) was 
analysed by IHC (Supplementary Figure 7). To investigate 
mechanisms underlying increased apoptosis associated 
with GSK2126458 treatment, expression of p53 and 
phosphorylation of MDM2 at S166 were analysed by IHC. 
Renal lesions appeared to have a lower level of p53 and 
decreased phosphorylation of MDM2 in rapamycin treated 
mice compared to vehicle treated mice while the protein 
level of p53 and the phosphorylation of MDM2 appeared 
to be similar in lesions of GSK2126458 treated mice 
to those of vehicle treated mice (Supplementary Figure 
8). Similar results were observed by Western analysis 
(Figure 5).
DISCUSSION
In this study, we investigated the therapeutic 
efficacy of GSK2126458 for renal tumours in Tsc2+/-
 mice in comparison to rapamycin. We demonstrated 
that GSK2126458 was effective for treating solid 
renal tumours. GSK2126458 has been used for treating 
Figure 6: Effect of GSK2126458 and rapamycin on proliferation and apoptosis of renal tumour cells in Tsc2+/- mice. 
Kidney sections were prepared from 14 months old Tsc2+/- mice after treatment and stained with antibody against Ki67 or active caspase-3 
by IHC to assess proliferation or apoptosis of tumour cells. Top left panel: Expression of Ki67 in renal tumours. Representative sections 
were presented to show expression of Ki67 in tumour cells after two months treatment with vehicle, GSK2126458 and rapamycin. Black 
lines are scale bars. Bottom left panel: Percentage of Ki67-positive tumour cells. Ten fields (20x) from 10 solid tumours were selected 
randomly from each group and examined for quantification of Ki67-positive tumour cells using ImageJ. Top right panel: Expression of 
active caspase 3 in renal tumours. Representative sections were presented to show expression of active caspase 3 in tumour cells after two 
months treatment with vehicle, GSK2126458 and rapamycin. Black lines are scale bars. Bottom right panel: Total area of active caspase 
3 positive tumour cells. Ten fields (20x) from 10 solid tumours were selected randomly from each group and examined for quantification 
of the total area of active caspase 3-positive tumour cells using ImageJ.
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xenograft tumours in immunocompromised mice and 
achieved significant therapeutic efficacy [8, 9]. We here 
used a genetically engineered Tsc2+/- mouse model that 
spontaneously develops various types of renal lesions 
and confirmed the anti-tumour efficacy of GSK2126458 
for tumours in an organ-appropriate environment. No 
previous comparison of anti-tumour efficacy between 
GSK2126458 and rapamycin has been made in vivo. 
GSK2126458 has been recently reported to be well 
tolerated in patients treated for multiple solid malignancy 
types with tumour responses and disease stabilization 
being seen [10]. Eight percent of these patients suffered 
diarrhoea and effective GSK2126458 dose remains to be 
determined. NVP-BEZ235, another ATP-competitive dual 
PI3K/mTOR inhibitor, has been used to treat renal lesions 
in a Tsc2+/- mouse model on the mixed C57BL/6J:129S1/
SvImJ background and appeared to be as effective as 
everolimus [14].
We found that GSK2126458 inhibited both 
mTORC1 and mTORC2 in all types of renal lesions in 
Tsc2+/- mice but the inhibitory effect of GSK2126458 
on mTORC1was weaker than that of rapamycin. 
GSK2126458 reduced phosphorylation of Akt at T308 but 
rapamycin did not. It remains to be determined whether 
this reduction in Akt phosphorylation contributes to anti-
tumour efficacy. GSK216458 has been reported to activate 
Erk1/2 in prostate cancer cells [15]. We did not observe 
increased activity of Erk1/2 in GSK2126458 treated renal 
lesions. In contrast, we found that the phosphorylation of 
RAF1 at S259, a part of the Erk1/2 signalling pathway, 
was reduced in GSK2126458 treated solid renal tumours.
Rapamycin has been reported to induce feedback 
activation of Akt in various cancer cells through 
increased phosphorylation at S473 by mTORC2 
and at T308 by PDK1 [6, 16 and 17]. We observed 
increased phosphorylation of Akt at S473 in over 50% 
of rapamycin treated cysts but not in solid tumours. No 
increased phosphorylation of Akt at T308 was detected 
in rapamycin treated solid tumours. In contrast, reduced 
phosphorylation of mTOR at S2481, another indicator of 
mTORC2 activation, was detected in rapamycin treated 
solid tumours. In a previous report, inhibition of mTORC1 
with everolimus led to a marked increase in Erk activity 
in breast cancer [17]. However, we found that the Erk1/2 
signalling was inhibited by rapamycin in solid renal 
tumours. These different observations may be partly 
related to the disruption of mTORC1 activation-associated 
feedback loops identified in renal lesions of Tsc2+/- mice 
[12].
We demonstrated that both GSK2126458 and 
rapamycin had anti-tumour efficacy by suppressing 
proliferation of tumour cells but suppression by rapamycin 
was much stronger than by GSK2126458, probably due 
to its inhibition of both mTOR and Erk/1/2 activities. 
We found that GSK2126458 promoted apoptosis in solid 
renal tumours. It may be of interest to determine the 
possible long term benefit after cessation of GSK2126458 
treatment. Previous studies have documented an increase 
in apoptosis and an increased ratio of p53/MDM2 in 
cancer cells following treatment with rapamycin [18]. We 
did not find that rapamycin increased apoptosis but did 
observe that rapamycin reduced the protein level of p53 
and the phosphorylation of MDM2 in solid renal tumours. 
Furthermore, we did not observe a significant change in 
the expression of p53 and phosphorylation of MDM2 
after GSK2126458 treatment, suggesting an alternative 
mechanism of apoptosis caused by GSK2126458. An 
in vitro study suggested that GSK2126458 increased 
responses of tumours to everolimus treatment [19]. It 
may therefore be worthwhile investigating whether 
combination of GSK2126458 with rapamycin could 
improve anti-tumour therapy through increased tumour 
cell death.
MATERIALS AND METHODS
Animal procedures
Animal procedures were performed in accordance 
with the UK Home Office guidelines and approved by 
the Ethical Review Group of Cardiff University. Tsc2+/− 
BALB/c mice were described previously [11]. Tsc2+/-
 litter mates were randomly allocated into 3 groups of 
10, balanced for gender and of the same age. Animals 
were treated with vehicle, GSK2126458 (2 mg/kg, 
MTD) and rapamycin (4 mg/kg) for 2 months from the 
age of 12 months via intraperitoneal injection 5 times a 
week. Animals were then sacrificed for assessment of 
tumour burden and analysis of protein expression and 
phosphorylation in normal tissues and tumour samples. 
GSK2126458 was purchased from Medkoo, Chapel Hill, 
USA and rapamycin from LC Laboratories, Woburn, MA, 
USA. GSK2126458 of 2 mg/ml and rapamycin of 2 mg/
ml were prepared respectively in 2.5% PEG-400, 2.5% 
Tween-80 and 2.5% DMSO.
Histology
Assessment of tumour burden in the kidneys of 
mice was performed as described previously [20]. Mouse 
kidneys were fixed in 10% buffered formalin saline for 24 
h. Fixed kidneys were processed and paraffin embedded. 
Six coronal sections of 5 μm were prepared at a 200 
μm interval from both kidneys of each mouse. Kidney 
sections were haematoxylin and eosin (HE)-stained 
and scanned to create virtual HE slides using an Aperio 
system (http://www.aperio.com/?gclid = CNXN-8by4a 
UCFcINfAods3eg1w). Virtual slides were used for lesion 
quantification. Maximum cross-sectional whole area (i.e. 
including intracystic spaces) and cellular area of each renal 
lesion were measured, respectively, using ImageJ (http://
rsbweb.nih.gov/ij). The assessment was conducted blindly 
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with respect to treatment status. The total and cellular 
burdens of all lesions were estimated from total whole 
areas and cellular areas respectively of all lesions (cystic, 
papillary and solid), and the burden of solid lesions alone 
was estimated from the sums of their cross sectional areas.
Immunohistochemistry (IHC) and Western blot
Immunohistochemistry (IHC) and Western blot were 
used to examine protein expression and phosphorylation, 
cell proliferation and apoptosis as described previously 
[12]. Kidney sections were prepared as above. SignalStain 
Boost Rabbit specific IHC Detection Reagent (Cell 
Signalling Technology, Danvers, USA) was used to stain 
antigens according to the kit supplier’s instruction. IHC 
stained slides were scanned to generate virtual slides 
for photo capture using an Aperio system. For Western 
blot, extracts of normal tissues and tumour samples were 
prepared using AllPrep DNA/RNA/Protein Mini Kit 
(QIAGEN Ltd-UK, Crawley, UK). Proteins were purified 
according to the kit supplier’s instruction. Twenty μg of 
protein per sample was separated on NuPAGE 4–12% 
Bis-Tris Gels (Fisher Scientific UK Ltd, Loughborough, 
UK) and transferred onto Amersham Protran Premium 
0.2 or 0.45 μm nitrocellulose blotting membranes(GE 
Healthcare UK Ltd, Little Chalfont, UK). Blots were 
analysed with ECL Select Western Detection Kit (GE 
Healthcare UK Ltd) and signals were detected using 
Autochemi Imaging System (UVP, Upland, CA, USA). 
Horseradish peroxidise-conjugated secondary antibody 
against rabbit was used for Western blot (Cell Signalling 
Technology Danvers, USA). Primary antibodies used for 
IHC and Western blot were those against phosphorylated 
S6 ribosomal protein at S235/236, 4E-BP1 at T37/46, 
4E-BP1 at S65, Akt at S473, Akt at T308, Akt substrates 
(RXXS*/T*), Akt substrates (RXRXXS*/T*) and Erk1/2 
at T202/Y204, 4E-BP1, p53 and β-actin (Cell Signalling 
Technology, Danvers, MA, USA);Ki67, active caspase 3, 
cleaved PARP, phosphorylated PKC at T638 and RAF1 at 
S259 ( Abcam, Cambridge, UK); phosphrylated MDM2 
at S166, mTOR at S2448 and mTOR at S2481 (Sigma-
Aldrich, Dorset, UK).
Statistical analysis
The Mann Whitney test was used to compare groups 
for statistical differences. P<0.05 was considered to be 
statistically significant. Analyses were performed using 
GraphPad Prism 7.01.
Abbreviation
TSC, tuberous sclerosis; PI3K, phosphoinositide 
3-kinase; mTOR, mechanistic target of rapamycin; 
mTORC1, mTOR complex 1; mTORC2, mTOR complex 
2; MAPK, mitogen-activated protein kinase;, AML, 
angiomyolipomas; IHC, immunohistochemistry; HE, 
haematoxylin and eosin; MDM2, Mouse double minute 2 
homolog; MTD, maximum tolerated dose.
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